<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-29183" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Social Anxiety Disorder</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Rose</surname>
            <given-names>Gregory M.</given-names>
          </name>
          <aff>University Hospital and Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Tadi</surname>
            <given-names>Prasanna</given-names>
          </name>
          <aff>Asram Medical College, Eluru, India</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Gregory Rose declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Prasanna Tadi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>25</day>
          <month>10</month>
          <year>2022</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-29183.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Social anxiety disorder (SAD) includes the essential feature of marked fear or anxiety of one or more social situations during which the individual may or may not be under scrutiny by others. Exposure to such a social situation almost always provokes fear or anxiety in the affected individual, and the individual experiences concern that they will be judged negatively. These individuals often avoid the social situations that they fear or endure with intense anxiety, which results in impairment in social, occupational, or other realms important to function in society. This activity describes the evaluation and treatment of social anxiety disorder and reviews the role of the interprofessional team in managing patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Examine&#x000a0;the etiology of social anxiety disorder.</p></list-item><list-item><p>Assess the evaluation of&#x000a0;social anxiety disorder.</p></list-item><list-item><p>Differentiate&#x000a0;the management options available for social anxiety disorder.</p></list-item><list-item><p>Communicate&#x000a0;interprofessional team strategies for improving care coordination and communication to educate patients and professionals about social anxiety disorder and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=29183&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=29183">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-29183.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Social anxiety disorder (SAD) is characterized by excessive fear of embarrassment, humiliation, or rejection&#x000a0;when exposed to possible negative evaluation by others&#x000a0;when engaged in a public performance or social interaction. It is also&#x000a0;known as social phobia. Over fifty years ago, in 1966, social&#x000a0;phobia was first&#x000a0;differentiated from agoraphobia and specific phobias. Since then, the concept has transformed from a relatively rare and neglected condition to&#x000a0;1 recognized as prevalent worldwide.<xref ref-type="bibr" rid="article-29183.r1">[1]</xref> The third edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-III) in 1980 described social phobia in a way that limited the diagnosis due to exclusionary criteria, including those with an avoidant personality disorder, a new category at the time. 1985, that view was challenged,&#x000a0;and by 1987, the&#x000a0; DSM-III-R removed the&#x000a0;exclusion.&#x000a0;In 1994, DSM-IV added the alternative name of SAD due to a recognition that social phobia could be differentiated from specific phobias due to important pathophysiological and clinical factors. With the publication of DSM-5 in 2013, SAD became the primary name.<xref ref-type="bibr" rid="article-29183.r2">[2]</xref>&#x000a0;With the publication of DSM-5, the diagnostic criteria for SAD have&#x000a0;been&#x000a0;broadened&#x000a0;from previous editions to include fear of acting in a way or showing anxiety symptoms that offend others or lead to rejection in addition to fear of humiliation or embarrassment.<xref ref-type="bibr" rid="article-29183.r3">[3]</xref>&#x000a0;The latest edition of DSM also removed the generalized subtype and added the "performance only" specifier.<xref ref-type="bibr" rid="article-29183.r4">[4]</xref></p>
      </sec>
      <sec id="article-29183.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Family and twin studies suggest that genetic factors' role as an etiological factor in&#x000a0;SAD is believed to be largely dependent on environmental factors.<xref ref-type="bibr" rid="article-29183.r5">[5]</xref>&#x000a0;Genetic markers have been difficult to identify. Parenting that is overly controlling or intrusive may result in inhibited temperament in children, increasing the risk for SAD. Adverse and stressful life events may also increase risk. A search for neurobiological&#x000a0;factors associated with SAD has been largely non-specific. Advances in neuroimaging technology may increase insight into the disorder in the future. Recent evidence suggests&#x000a0;an extended amygdala is an essential region in anxiety disorders.<xref ref-type="bibr" rid="article-29183.r1">[1]</xref></p>
      </sec>
      <sec id="article-29183.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Epidemiological studies have shown that&#x000a0;SAD has a worldwide prevalence&#x000a0;of 5 to 10% and a lifetime prevalence of 8.4 to 15%.<xref ref-type="bibr" rid="article-29183.r6">[6]</xref>&#x000a0;Prevalence rates are comparable within the United States. The prevalence rates in children and adolescents are&#x000a0;similar to those of adults.&#x000a0;SAD more commonly affects women than men.&#x000a0;SAD is the third most common mental disorder behind substance use disorder and depression and is the most common anxiety disorder.<xref ref-type="bibr" rid="article-29183.r7">[7]</xref></p>
      </sec>
      <sec id="article-29183.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Studies in the past have found that persons with performance-type&#x000a0;SAD may have a greater response to the autonomic nervous system, including elevated heart rate.<xref ref-type="bibr" rid="article-29183.r8">[8]</xref> Additionally, multiple neurotransmitter systems, including serotonin, dopamine, and glutamate, may be implicated in the pathogenesis of SAD.<xref ref-type="bibr" rid="article-29183.r9">[9]</xref><xref ref-type="bibr" rid="article-29183.r10">[10]</xref> Brain imaging of those with&#x000a0;SAD reveals increased paralimbic and limbic circuitry activity.<xref ref-type="bibr" rid="article-29183.r11">[11]</xref> Certain temperaments of toddlers and maternal stress have also been shown to be associated with persons who develop SAD.<xref ref-type="bibr" rid="article-29183.r12">[12]</xref></p>
      </sec>
      <sec id="article-29183.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>The majority of individuals with&#x000a0;SAD&#x000a0;report the&#x000a0;onset of symptoms before 20 years old when obtaining a history. Many report symptoms beginning in early childhood. Social anxiety is a chronic disorder, typically lasting for 6 months or more. Individuals with SAD are more likely to be less educated, unmarried, and have lower socioeconomic status. Additionally, many patients with SAD may not seek treatment because they believe the social anxiety to be part of their personality structure and, therefore, does not require treatment.<xref ref-type="bibr" rid="article-29183.r7">[7]</xref>&#x000a0;Patients with SAD frequently present to physicians because of other disorders, including major depression or substance use&#x000a0;and related disorders.<xref ref-type="bibr" rid="article-29183.r5">[5]</xref></p>
      </sec>
      <sec id="article-29183.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Evaluation of&#x000a0;SAD must include its diagnostic criteria&#x000a0;as classified in the Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM-5). Criteria include pronounced fear or anxiety around&#x000a0;1 or multiple social situations where a person is possibly exposed to the possible scrutiny of others. The person fears they may act in a way that may be evaluated negatively. The social situation, for the most part, provokes anxiety or fear. The situations are either endured with anxiety or fear or avoided entirely. This fear or anxiety is disproportionate to the threat posed by the situation. The avoidance, fear, or anxiety typically lasts for at least 6 months and causes significant impairment or distress in an important area of functioning. The fear must not be attributable to the effects of a substance or medical condition or the symptoms of a different mental disorder. Additionally, the anxiety, avoidance, or fear is excessive or unrelated if a separate medical condition is present. There is a performance-only specifier if fear is restricted exclusively to performing or speaking in public.</p>
        <p>A core feature of SAD is the fear of negative evaluation. Instruments that assess for SAD include but are not limited to the Social Phobia Inventory (SPIN), Mini-SPIN, Liebowitz Social Anxiety Scale (LSAS), Liebowitz Self-Rated Disability Scale, Disability Profile,&#x000a0;Brief Social Phobia Scale (BSPS), and Social Phobia Safety Behaviors Scale and Self Statements During Public Speaking Scale.<xref ref-type="bibr" rid="article-29183.r13">[13]</xref>&#x000a0;There is evidence that the items on SPIN capture multiple symptoms of SAD, including fear of negative evaluation, distress as a result of physical symptoms of anxiety, and the fear of uncertainty when in social situations.<xref ref-type="bibr" rid="article-29183.r14">[14]</xref>&#x000a0;Patients with SAD may speak quietly or offer cursory answers to questions. In addition, eye contact is often less than normal. Often, individuals with SAD reveal their symptoms with direct questioning.<xref ref-type="bibr" rid="article-29183.r15">[15]</xref></p>
      </sec>
      <sec id="article-29183.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>There is a large amount of evidence supporting the efficacy of medications and cognitive behavioral therapy (CBT) in SAD.<xref ref-type="bibr" rid="article-29183.r15">[15]</xref>&#x000a0;According to meta-analysis, SAD responds well to treatment with individual CBT and selective serotonin reuptake inhibitors (SSRI). Additionally, serotonin-norepinephrine reuptake inhibitors (SNRIs) have a greater effect on outcomes than placebo. The SSRIs sertraline and paroxetine, as well as the SNRI venlafaxine, have been approved by the FDA. Comparing different psychotherapies, SAD responded better to CBT than psychodynamic therapy and other psychological therapies. The beta-blocker propranolol, as well as benzodiazepines, are also used in the treatment of SAD. Propranolol has the advantage of being used on an as-needed basis without the risk of developing dependence and tolerance, as exists with benzodiazepines. There is no evidence that combining pharmacological and psychological interventions is more efficacious than monotherapy.<xref ref-type="bibr" rid="article-29183.r16">[16]</xref> A comparison of pharmacotherapy and psychotherapy trials suggests medication has faster effects, but&#x000a0;CBT has longer-lasting effects.<xref ref-type="bibr" rid="article-29183.r15">[15]</xref></p>
      </sec>
      <sec id="article-29183.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>SAD&#x000a0;must be differentiated from other disorders, including neurodevelopment disorders such as autism spectrum disorder, panic disorder and agoraphobia, depressive disorders, substance-related and addictive disorders, body dysmorphic disorder, and personality disorders such as schizoid personality disorder&#x000a0;and avoidant personality disorder. As indicated in the DSM-5 criteria, to make a diagnosis of SAD, the individual's symptoms must not be better explained by symptoms of another mental disorder. Other diagnoses to&#x000a0;rule out include hikikomori, an extreme form of social withdrawal lasting more than 6 months, occurring among 1.2% of adults in Japan, and schizophrenia.<xref ref-type="bibr" rid="article-29183.r5">[5]</xref></p>
      </sec>
      <sec id="article-29183.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Left untreated,&#x000a0;SAD is recognized as a debilitating and highly prevalent disorder that may result in lower educational attainment, worse occupational performance, hampered social interaction, lower-quality relationships, and decreased quality of life. SAD is associated with suicidal ideation, low self-esteem, lower socioeconomic status, unemployment, financial issues, and being unmarried. Many individuals with SAD are not aware of their mental health problems&#x000a0;and, therefore, do not seek treatment.<xref ref-type="bibr" rid="article-29183.r17">[17]</xref><xref ref-type="bibr" rid="article-29183.r18">[18]</xref></p>
      </sec>
      <sec id="article-29183.s11" sec-type="Complications">
        <title>Complications</title>
        <p>Comorbid psychiatric disorders occur in up to 90% of patients with SAD. SAD's presence is a predictor for the development of major depression and alcohol use disorder. Patients who have comorbid psychiatric disorders have an increased likelihood of greater severity of symptoms, treatment resistance, decreased functioning, and increased rates of suicide.<xref ref-type="bibr" rid="article-29183.r6">[6]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-29183.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Many patients with&#x000a0;SAD do not realize they have a treatable illness and, therefore, do not seek treatment. Patient education, including public education, is essential to treating and preventing this disorder.<xref ref-type="bibr" rid="article-29183.r7">[7]</xref></p>
      </sec>
      <sec id="article-29183.s13" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>As discussed, educating patients and the public is vital to managing and preventing SAD. Recognition of SAD is poor and requires&#x000a0;more effort from healthcare professionals to recognize it, as individuals with the disorder are unlikely to self-report it due to their symptoms. SAD is the third most&#x000a0;common mental illness, affecting a significant proportion of the general population in their lifetimes. An important role of a primary care physician is to recognize the illness and either treat the disorder themselves or refer to a mental health specialist who has experience with the condition.<xref ref-type="bibr" rid="article-29183.r19">[19]</xref>&#x000a0;Evidence shows that&#x000a0;SAD is highly treatable with either cognitive behavioral therapy (CBT) or pharmacotherapy in the form of SSRIs and SNRIs or beta-blockers.<xref ref-type="bibr" rid="article-29183.r16">[16]</xref></p>
      </sec>
      <sec id="article-29183.s14">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=29183&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=29183">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/mental-health/social-anxiety-disorder/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=29183">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/29183/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=29183">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-29183.s15">
        <title>References</title>
        <ref id="article-29183.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hyett</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>McEvoy</surname>
                <given-names>PM</given-names>
              </name>
            </person-group>
            <article-title>Social anxiety disorder: looking back and moving forward.</article-title>
            <source>Psychol Med</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>48</volume>
            <issue>12</issue>
            <fpage>1937</fpage>
            <page-range>1937-1944</page-range>
            <pub-id pub-id-type="pmid">29321077</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29183.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>B&#x000f6;gels</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Alden</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Beidel</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Pine</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Stein</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Voncken</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Social anxiety disorder: questions and answers for the DSM-V.</article-title>
            <source>Depress Anxiety</source>
            <year>2010</year>
            <month>Feb</month>
            <volume>27</volume>
            <issue>2</issue>
            <fpage>168</fpage>
            <page-range>168-89</page-range>
            <pub-id pub-id-type="pmid">20143427</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29183.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heimberg</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Hofmann</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Liebowitz</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Schneier</surname>
                <given-names>FR</given-names>
              </name>
              <name>
                <surname>Smits</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Stein</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Hinton</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Craske</surname>
                <given-names>MG</given-names>
              </name>
            </person-group>
            <article-title>Social anxiety disorder in DSM-5.</article-title>
            <source>Depress Anxiety</source>
            <year>2014</year>
            <month>Jun</month>
            <volume>31</volume>
            <issue>6</issue>
            <fpage>472</fpage>
            <page-range>472-9</page-range>
            <pub-id pub-id-type="pmid">24395386</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29183.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boyers</surname>
                <given-names>GB</given-names>
              </name>
              <name>
                <surname>Broman-Fulks</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Valentiner</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>McCraw</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Curtin</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Michael</surname>
                <given-names>KD</given-names>
              </name>
            </person-group>
            <article-title>The latent structure of social anxiety disorder and the performance only specifier: a taxometric analysis.</article-title>
            <source>Cogn Behav Ther</source>
            <year>2017</year>
            <month>Nov</month>
            <volume>46</volume>
            <issue>6</issue>
            <fpage>507</fpage>
            <page-range>507-521</page-range>
            <pub-id pub-id-type="pmid">28641059</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29183.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nagata</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Suzuki</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Teo</surname>
                <given-names>AR</given-names>
              </name>
            </person-group>
            <article-title>Generalized social anxiety disorder: A still-neglected anxiety disorder 3 decades since Liebowitz's review.</article-title>
            <source>Psychiatry Clin Neurosci</source>
            <year>2015</year>
            <month>Dec</month>
            <volume>69</volume>
            <issue>12</issue>
            <fpage>724</fpage>
            <page-range>724-40</page-range>
            <pub-id pub-id-type="pmid">26121185</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29183.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Koyuncu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>&#x00130;nce</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ertekin</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>T&#x000fc;kel</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Comorbidity in social anxiety disorder: diagnostic and therapeutic challenges.</article-title>
            <source>Drugs Context</source>
            <year>2019</year>
            <volume>8</volume>
            <fpage>212573</fpage>
            <pub-id pub-id-type="pmid">30988687</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29183.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sareen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Stein</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>A review of the epidemiology and approaches to the treatment of social anxiety disorder.</article-title>
            <source>Drugs</source>
            <year>2000</year>
            <month>Mar</month>
            <volume>59</volume>
            <issue>3</issue>
            <fpage>497</fpage>
            <page-range>497-509</page-range>
            <pub-id pub-id-type="pmid">10776832</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29183.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hofmann</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Newman</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Ehlers</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Roth</surname>
                <given-names>WT</given-names>
              </name>
            </person-group>
            <article-title>Psychophysiological differences between subgroups of social phobia.</article-title>
            <source>J Abnorm Psychol</source>
            <year>1995</year>
            <month>Feb</month>
            <volume>104</volume>
            <issue>1</issue>
            <fpage>224</fpage>
            <page-range>224-31</page-range>
            <pub-id pub-id-type="pmid">7897046</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29183.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schneier</surname>
                <given-names>FR</given-names>
              </name>
              <name>
                <surname>Abi-Dargham</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Martinez</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Slifstein</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hwang</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Liebowitz</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Laruelle</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Dopamine transporters, D2 receptors, and dopamine release in generalized social anxiety disorder.</article-title>
            <source>Depress Anxiety</source>
            <year>2009</year>
            <volume>26</volume>
            <issue>5</issue>
            <fpage>411</fpage>
            <page-range>411-8</page-range>
            <pub-id pub-id-type="pmid">19180583</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29183.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Phan</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Fitzgerald</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Cortese</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Seraji-Bozorgzad</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Tancer</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>GJ</given-names>
              </name>
            </person-group>
            <article-title>Anterior cingulate neurochemistry in social anxiety disorder: 1H-MRS at 4 Tesla.</article-title>
            <source>Neuroreport</source>
            <year>2005</year>
            <month>Feb</month>
            <day>08</day>
            <volume>16</volume>
            <issue>2</issue>
            <fpage>183</fpage>
            <page-range>183-6</page-range>
            <pub-id pub-id-type="pmid">15671874</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29183.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Furmark</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tillfors</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Marteinsdottir</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Fischer</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Pissiota</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>L&#x000e5;ngstr&#x000f6;m</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Fredrikson</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Common changes in cerebral blood flow in patients with social phobia treated with citalopram or cognitive-behavioral therapy.</article-title>
            <source>Arch Gen Psychiatry</source>
            <year>2002</year>
            <month>May</month>
            <volume>59</volume>
            <issue>5</issue>
            <fpage>425</fpage>
            <page-range>425-33</page-range>
            <pub-id pub-id-type="pmid">11982446</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29183.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Essex</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Slattery</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Goldsmith</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Kalin</surname>
                <given-names>NH</given-names>
              </name>
            </person-group>
            <article-title>Early risk factors and developmental pathways to chronic high inhibition and social anxiety disorder in adolescence.</article-title>
            <source>Am J Psychiatry</source>
            <year>2010</year>
            <month>Jan</month>
            <volume>167</volume>
            <issue>1</issue>
            <fpage>40</fpage>
            <page-range>40-6</page-range>
            <pub-id pub-id-type="pmid">19917594</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29183.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Os&#x000f3;rio</surname>
                <given-names>Fde L</given-names>
              </name>
              <name>
                <surname>Crippa</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Loureiro</surname>
                <given-names>SR</given-names>
              </name>
            </person-group>
            <article-title>Instruments for the assessment of social anxiety disorder: Validation studies.</article-title>
            <source>World J Psychiatry</source>
            <year>2012</year>
            <month>Oct</month>
            <day>22</day>
            <volume>2</volume>
            <issue>5</issue>
            <fpage>83</fpage>
            <page-range>83-5</page-range>
            <pub-id pub-id-type="pmid">24175172</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29183.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Campbell-Sills</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Espejo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ayers</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Roy-Byrne</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Stein</surname>
                <given-names>MB</given-names>
              </name>
            </person-group>
            <article-title>Latent dimensions of social anxiety disorder: A re-evaluation of the Social Phobia Inventory (SPIN).</article-title>
            <source>J Anxiety Disord</source>
            <year>2015</year>
            <month>Dec</month>
            <volume>36</volume>
            <fpage>84</fpage>
            <page-range>84-91</page-range>
            <pub-id pub-id-type="pmid">26454660</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29183.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stein</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Stein</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Social anxiety disorder.</article-title>
            <source>Lancet</source>
            <year>2008</year>
            <month>Mar</month>
            <day>29</day>
            <volume>371</volume>
            <issue>9618</issue>
            <fpage>1115</fpage>
            <page-range>1115-25</page-range>
            <pub-id pub-id-type="pmid">18374843</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29183.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mayo-Wilson</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Dias</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mavranezouli</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Kew</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Ades</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Pilling</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Psychological and pharmacological interventions for social anxiety disorder in adults: a systematic review and network meta-analysis.</article-title>
            <source>Lancet Psychiatry</source>
            <year>2014</year>
            <month>Oct</month>
            <volume>1</volume>
            <issue>5</issue>
            <fpage>368</fpage>
            <page-range>368-76</page-range>
            <pub-id pub-id-type="pmid">26361000</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29183.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Iverach</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Rapee</surname>
                <given-names>RM</given-names>
              </name>
            </person-group>
            <article-title>Social anxiety disorder and stuttering: current status and future directions.</article-title>
            <source>J Fluency Disord</source>
            <year>2014</year>
            <month>Jun</month>
            <volume>40</volume>
            <fpage>69</fpage>
            <page-range>69-82</page-range>
            <pub-id pub-id-type="pmid">24929468</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29183.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cuijpers</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>van Straten</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Improving outcomes in social anxiety disorder.</article-title>
            <source>Lancet Psychiatry</source>
            <year>2014</year>
            <month>Oct</month>
            <volume>1</volume>
            <issue>5</issue>
            <fpage>324</fpage>
            <page-range>324-6</page-range>
            <pub-id pub-id-type="pmid">26360985</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29183.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zamorski</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Ward</surname>
                <given-names>RK</given-names>
              </name>
            </person-group>
            <article-title>Social anxiety disorder: common, disabling, and treatable.</article-title>
            <source>J Am Board Fam Pract</source>
            <year>2000</year>
            <season>Jul-Aug</season>
            <volume>13</volume>
            <issue>4</issue>
            <fpage>251</fpage>
            <page-range>251-60</page-range>
            <pub-id pub-id-type="pmid">10933289</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
